Call for Expressions of Interest for scientific research grants focused on clinical use or innovation in plasma exchange therapy
LAKEWOOD, Colo.—January 25, 2012—CaridianBCT and Terumo Transfusion, which are uniting to become Terumo BCT, have announced the launch of the Plasma Exchange Innovation Award . The award is part of a new program that will give one or more grants up to $100,000 to fund science and research that furthers innovation that will generate greater understanding in the use of plasma exchange, or plasmapheresis. This work can be in the fields of neurology, immunology, hematology and other fields of medicine. The organization is now accepting Expressions of Interest , with a May 4, 2012 deadline.
The Plasma Exchange Innovation Award is intended to encourage the investigation of novel scientific ideas, best practices, tools and standards that have the potential to substantially advance the understanding and the use of plasma exchange
Applicants must submit
an Expression of Interest by May 4th to be considered for the award
The Grant Committee will request all finalists to complete a Full Submission; the Grant Committee consists of two representatives of the CaridianBCT Medical Affairs team and three independent specialists
All Expressions of Interest submitted will be reviewed by the Grant Committee
Each application will be reviewed based on the fundamentals of scientific merit, availability of funds and relevance to award program priorities, as well other application criteria
Grant administrators reserve the right to withhold all or partial grant funds based on the quality of submissions
Eric Buenz, Ph.D., Director, Medical Affairs, CaridianBCT and Terumo Transfusion
"We are excited to announce the Plasma Exchange Innovation Award and the opportunity to provide support to the dedicated individuals in the field of medicine whose cutting-edge work we can support, thereby encouraging a better understanding of the efficacy and use of plasma exchange, new clinical uses and most importantly, new, innovative thinking."
About Terumo BCT:
CaridianBCT and Terumo Transfusion are becoming Terumo BCT, the world leader in blood component technology. Together, we believe in the potential of blood to do even more for the world than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers to ultimately benefit the patients we all serve. The transition to Terumo BCT will be complete in April 2012.
Global Corporate Communications